$-0.92 EPS Expected for Achaogen, Inc. (AKAO); Intersections (INTX)’s Sentiment Is 0.56

April 13, 2018 - By Richard Conner

Achaogen, Inc. (NASDAQ:AKAO) Logo

Analysts expect Achaogen, Inc. (NASDAQ:AKAO) to report $-0.92 EPS on May, 14.They anticipate $0.41 EPS change or 80.39% from last quarter’s $-0.51 EPS. After having $-0.98 EPS previously, Achaogen, Inc.’s analysts see -6.12% EPS growth. The stock increased 5.93% or $0.695 during the last trading session, reaching $12.415. About 1.15 million shares traded or 0.54% up from the average. Achaogen, Inc. (NASDAQ:AKAO) has declined 41.74% since April 13, 2017 and is downtrending. It has underperformed by 53.29% the S&P500.

Intersections Inc (INTX) investors sentiment increased to 0.56 in 2017 Q4. It’s up 0.11, from 0.45 in 2017Q3. The ratio has improved, as 5 hedge funds increased and opened new positions, while 9 reduced and sold their holdings in Intersections Inc. The hedge funds in our database now hold: 5.95 million shares, down from 6.07 million shares in 2017Q3. Also, the number of hedge funds holding Intersections Inc in top ten positions was flat from 1 to 1 for the same number . Sold All: 3 Reduced: 6 Increased: 4 New Position: 1.

Since December 18, 2017, it had 9 insider purchases, and 5 selling transactions for $10.50 million activity. 49,660 shares were bought by DUGGAN ROBERT W, worth $564,244. On Wednesday, February 21 the insider Hillan Kenneth J. sold $49,146. $17,499 worth of Achaogen, Inc. (NASDAQ:AKAO) was sold by Wise Blake on Wednesday, February 21. On Wednesday, February 21 the insider Swem Lee sold $13,679. $11,822 worth of Achaogen, Inc. (NASDAQ:AKAO) shares were sold by Schilke Tobin.

Investors sentiment increased to 1.32 in Q4 2017. Its up 0.16, from 1.16 in 2017Q3. It increased, as 16 investors sold Achaogen, Inc. shares while 21 reduced holdings. 22 funds opened positions while 27 raised stakes. 29.75 million shares or 6.36% less from 31.77 million shares in 2017Q3 were reported. Fmr Llc has 5.03 million shares. Quantitative Inv Llc reported 133,500 shares or 0.02% of all its holdings. 7,287 were accumulated by Bnp Paribas Arbitrage. Polar Llp has invested 0.21% in Achaogen, Inc. (NASDAQ:AKAO). Manufacturers Life Insurance Com The holds 0% or 26,721 shares in its portfolio. Parallax Volatility Advisers Ltd Partnership accumulated 0% or 5,308 shares. Metropolitan Life Insur Ny stated it has 0% in Achaogen, Inc. (NASDAQ:AKAO). Winch Advisory Serv Limited Liability holds 0% of its portfolio in Achaogen, Inc. (NASDAQ:AKAO) for 200 shares. Ny State Common Retirement Fund invested 0% of its portfolio in Achaogen, Inc. (NASDAQ:AKAO). Fiera Capital invested 0.01% in Achaogen, Inc. (NASDAQ:AKAO). Baker Bros Advisors L P holds 0.01% or 122,482 shares. Hikari Pwr owns 60,000 shares. Regions Finance holds 0% or 4,500 shares in its portfolio. Lord Abbett And Company Llc, a New Jersey-based fund reported 366,247 shares. Iconiq Capital Lc holds 0.03% of its portfolio in Achaogen, Inc. (NASDAQ:AKAO) for 28,629 shares.

Achaogen, Inc., a late-stage biopharmaceutical company, discovers, develops, and commercializes antibacterials to treat multi-drug resistant gram-negative infections in the United States. The company has market cap of $555.27 million. The firm is principally developing plazomicin, which is in Phase III clinical trial for the treatment of serious bacterial infections, including urinary tract infections, blood stream infections, and other infections due to MDR Enterobacteriaceae comprising carbapenem-resistant Enterobacteriaceae. It currently has negative earnings. It is also involved in the research and development of antipseudomonal LpxC inhibitor compounds for the treatment of bacterial infections; and therapeutic antibody discovery program.

Among 10 analysts covering Achaogen (NASDAQ:AKAO), 9 have Buy rating, 1 Sell and 0 Hold. Therefore 90% are positive. Achaogen had 25 analyst reports since March 16, 2016 according to SRatingsIntel. The stock of Achaogen, Inc. (NASDAQ:AKAO) has “Buy” rating given on Wednesday, February 28 by Stifel Nicolaus. The stock of Achaogen, Inc. (NASDAQ:AKAO) earned “Buy” rating by Cowen & Co on Thursday, June 1. The stock has “Outperform” rating by Leerink Swann on Monday, October 9. The rating was maintained by Wedbush on Wednesday, February 14 with “Buy”. The firm earned “Buy” rating on Wednesday, February 28 by Needham. The company was initiated on Wednesday, November 2 by Aegis Capital. Wedbush maintained Achaogen, Inc. (NASDAQ:AKAO) rating on Wednesday, February 1. Wedbush has “Outperform” rating and $23 target. On Tuesday, January 2 the stock rating was maintained by Cowen & Co with “Buy”. Stifel Nicolaus maintained the stock with “Buy” rating in Thursday, August 3 report. The rating was upgraded by Wedbush to “Outperform” on Tuesday, June 14.

Intersections Inc. provides identity risk management and privacy protection services in the United States and Canada. The company has market cap of $47.96 million. The companyÂ’s Personal Information Services segment offers privacy, personal information security, and identity theft monitoring and remediation services for clients to understand, monitor, manage, and protect against the risks associated with their personal information. It currently has negative earnings. The Company’s services include credit reports, credit monitoring, educational credit scores, and credit education; reports, monitoring, and education about other personal information and risks, such as public records, identity validation, new accounts, and Internet data risks; identity theft recovery services; identity theft cost reimbursement insurance; and software and other technology tools and services under the IDENTITY GUARD brand.

The stock increased 2.06% or $0.04 during the last trading session, reaching $1.98. About 13,429 shares traded. Intersections Inc. (INTX) has declined 54.46% since April 13, 2017 and is downtrending. It has underperformed by 66.01% the S&P500.

Intersections Inc. (NASDAQ:INTX) Institutional Positions Chart

Echostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>